I see that some are pointing to DXB as a comparison, (I used to be in DXB, but made my money and got out) but DXB, while it has an awesome and important product, doesn't have:
phase 3 trial results;
FDA approval;
A product that is already selling in another jurisdiction;
strong sales results there;
a sales team and support network ready to go and primed for success.
DXB does have Nina, and she is brilliant.
BOT, as I have said before, will paddle its own canoe.
The CR may be an inconvenience for some, but it is seriously only a blip, but it is, as has been pointed out by others, an important step in maximising any return from any buyout that may appear on the horizon.
- Forums
- ASX - By Stock
- BOT
- Ann: FDA Approves Sofdra
Ann: FDA Approves Sofdra, page-286
-
- There are more pages in this discussion • 269 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BOT (ASX) to my watchlist
|
|||||
Last
36.5¢ |
Change
-0.010(2.67%) |
Mkt cap ! $678.7M |
Open | High | Low | Value | Volume |
37.5¢ | 38.0¢ | 36.0¢ | $384.0K | 1.043M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
21 | 683897 | 36.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
36.5¢ | 338019 | 14 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
10 | 222017 | 0.365 |
15 | 603288 | 0.360 |
16 | 571934 | 0.355 |
31 | 929650 | 0.350 |
12 | 1765286 | 0.345 |
Price($) | Vol. | No. |
---|---|---|
0.370 | 212796 | 4 |
0.375 | 344294 | 5 |
0.380 | 706786 | 10 |
0.385 | 884930 | 11 |
0.390 | 868327 | 9 |
Last trade - 10.34am 31/07/2024 (20 minute delay) ? |
Featured News
BOT (ASX) Chart |
The Watchlist
MTL
MANTLE MINERALS LIMITED
Nick Poll, Executive Director
Nick Poll
Executive Director
SPONSORED BY The Market Online